Literature DB >> 28109853

Variants of estrogen receptor alpha and beta genes modify the severity of sporadic breast cancer.

Luciana Montes Rezende1, Fernando Augusto Lima Marson2, Carmen Sílvia Passos Lima3, Carmen Sílvia Bertuzzo4.   

Abstract

INTRODUCTION: Reproductive factors pose a risk for sporadic breast cancer (BC) development owing to the lifetime exposure to estrogen, a hormone responsible for cell proliferation in the breast. Because variants of the estrogen receptor (ER) alpha and beta genes have been associated with BC risk in numerous populations, the objective of the study was to determine whether the risk and severity of sporadic BC was associated with the rs2228480 (ESR1) and rs4986938 (ESR2) variants in a Brazilian population.
METHODS: A total of 253 DNA samples from sporadic BC patients and 257 DNA samples from healthy controls were studied. The samples were genotyped by PCR-RFLP. Epidemiological, clinical, and reproductive factors were analyzed. Statistical tests conducted included the χ2 test, Fisher's exact test, and Mann-Whitney and Kruskal-Wallis tests or their parametric equivalents.
RESULTS: There was a high frequency of the rs2228480*GG genotype among the ER-positive tumors (OR=2.13; 95% CI=1.189-3.816) and it showed minor association with clinical stage 0 (OR=0.324; 95% CI=0.116-0.904). The rs2228480*GA genotype was associated with minor ER expression, whereas rs2228480*GG was associated with high expression of the progesterone receptor (PR). The frequency of rs4986938*GA was high among women who breastfed (OR=2.11; 95% CI=1.203-3.702), and it showed high association with clinical stage 0 (OR=4.383; 95% CI=1.606-11.96) whereas it had minor association with systemic arterial hypertension (OR=0.53; 95% CI=0.319-0.880). The rs2228480*GG/rs4986938*GG haplotype occurred at a low frequency among women who breastfed (OR=0.525; 95% CI=0.298-0.924) but it was associated with a high expression of PR.
CONCLUSION: The rs2228480 and rs4986938 variants did not alter sporadic BC risk, but they did modulate the BC severity.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ESR1; ESR2; Modifier gene; Neoplasia; Risk factor

Mesh:

Substances:

Year:  2017        PMID: 28109853     DOI: 10.1016/j.gene.2017.01.010

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  3 in total

1.  ESR2 gene variants (rs1256049, rs4986938, and rs1256030) and their association with breast cancer risk.

Authors:  Martha Patricia Gallegos-Arreola; Guillermo M Zúñiga-González; Luis E Figuera; Ana María Puebla-Pérez; María Guadalupe Márquez-Rosales; Belinda Claudia Gómez-Meda; Mónica Alejandra Rosales-Reynoso
Journal:  PeerJ       Date:  2022-05-10       Impact factor: 3.061

Review 2.  No Association between Estrogen Receptor-Β Rs4986938 and Cancer Risk: A Systematic Review and Meta-Analysis.

Authors:  Zhaofang Li; Xiaoli Yang; Rongqiang Zhang; Dandan Zhang; Baorong Li; Di Zhang; Qiang Li; Yongmin Xiong
Journal:  Iran J Public Health       Date:  2019-05       Impact factor: 1.429

3.  Association between estrogen receptor β polymorphisms and prostate cancer in a Slovak population.

Authors:  Jana Jurečeková; Monika Kmeťová Sivoňová; Henrieta Drobková; Márk Híveš; Daniel Evin; Ján Kliment; Dušan Dobrota
Journal:  Oncol Lett       Date:  2021-01-19       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.